CEO, Dr James Garner’s presentation to H.C. Wainwright 22nd Annual Global Investment Conference watch here
CEO, Dr James Garner discusses our recent significant milestones for paxalisib with Share Cafe click here
Dr Matt Dun, and CEO, Dr James Garner discuss the development of paxalisib for DIPG on Channel 7’s Sunrise watch here
Kazia is collaborating with leading research institutes and hospitals to bring new patient therapies to life read more
Learn why paxalisib is a novel potential treatment for glioblastoma brain cancer read more
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.